Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy.

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation

Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation

Prevention and Treatment Strategies of Postoperative Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Liver Transplantation for Hepatocellular Carcinoma: A Prognostic Model Incorporating Pretransplant Inflammatory Cytokines.

The impact of biological features for a better prediction of posttransplant hepatocellular cancer recurrence

Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients

Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma: Prevention and Treatment

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

A Single‐center Retrospective Analysis of Liver Transplantation on 255 Patients with Hepatocellular Carcinoma

A Prognostic Fingerprint in Liver Transplantation for Hepatocellular Carcinoma Based on Plasma Metabolomics Profiling.

[Multivariate Analysis of Recurrence of Hepatocellular Carcinoma after Liver Transplantation].

Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

[The Mechanism and Current Strategies for Preventing the Recurrence of Hepatocellular Carcinoma after Liver Transplantation].

Prevention and Management of Recurrence and Metastasis of Hepatocellular Carcinoma after Liver Transplantation

Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a singlecenter study.